May 10, 2017 06:16 AM EDT

In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study

John Carroll

Editor & Founder

Genentech put the A team on their PD-L1 checkpoint program for Tecentriq (atezolizumab), building a pipeline of combinations now in the clinic as they …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study

John Carroll

Editor & Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

In a stun­ning set­back, Roche says its top can­cer drug Tecen­triq failed a key PhI­II study

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study